BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• 

  Job Trends

  Life sciences still falls short on pay equity

  Women and nonwhite racial/ethnic groups are still earning less in the life sciences. An industry consultant discusses the pay disparities, ways to fix the gaps and why change is needed.

  April 23, 2026

   · 

  5 min read

   · 

  Angela Gabriel
• 

  Job Trends

  11 companies hiring in Illinois now

  Looking for a biopharma job in Illinois? Check out the BioSpace list of 11 companies hiring life sciences professionals like you.

  April 23, 2026

   · 

  2 min read

   · 

  Angela Gabriel
• 

  Job Trends

  Washington’s life sciences jobs continue increasing, up 50% from 2014-2024: report

  While life sciences employment was down 0.3% nationally in 2024, it rose 1.9% in Washington, according to a new Life Science Washington report. The association’s CEO discusses the latest findings and how the state’s job market looks this year.

  April 23, 2026

   · 

  3 min read

   · 

  Angela Gabriel
• 

  Manufacturing

  AbbVie commits $1.4B to NC plant in its largest-ever single campus investment

  The Durham plant will manufacture immunology, neuroscience and oncology drugs once AbbVie finishes construction in 2028.

  April 23, 2026

   · 

  2 min read

   · 

  Nick Paul Taylor
• 

  Neuroscience

  AAN 2026: J&J, Kyverna, Capricor and Praxis showcase practice-changing data

  This year’s American Academy of Neurology meeting included a presentation that could one day set a new treatment standard for myasthenia gravis.

  April 23, 2026

   · 

  4 min read

   · 

  Tristan Manalac
• 

  Obesity

  Roche insists amylin obesity drug still valuable for patients who ‘don’t want side effects’

  Roche and Zealand Pharma announced last month that their amylin analog petrelintide elicited a 9% placebo-controlled weight reduction at 42 weeks—falling far below analyst and investor expectations.

  April 23, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Complete response letters

  Unnamed pharma files citizen petition targeting FDA’s trove of rejection letters

  The FDA in July 2025 made publicly available over 200 complete response letters—an initiative that the investment community sees as “unanimously positive,” analysts told BioSpace.

  April 23, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Earnings

  Sanofi defends Dupixent patents, but execs insist it has nothing to do with CEO change

  Sanofi’s interim leadership sought on a Thursday earnings call to quell concerns that its sudden defense of Dupixent’s patents had anything to do with the departure of CEO Paul Hudson.

  April 23, 2026

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  Leadership

  BBOT shakes up leadership as RAS competitors get more visibility

  Chief Scientific Officer Pedro Beltran will succeed Eli Wallace as CEO of BridgeBio Oncology Therapeutics, as the board eyes a busy period of clinical advancement in the RAS oncology space.

  April 23, 2026

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Deals

  Amneal inks $1.1B Kashiv buyout to pursue biosimilar market leadership

  The takeover will give Amneal control of four facilities to manufacture biosimilars for a planned wave of launches in the coming years.

  April 23, 2026

   · 

  2 min read

   · 

  Nick Paul Taylor